Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Pharmaceutical professionals say employee safety and supply chain disruption are top COVID-19 concerns in latest GlobalData survey

Pharmaceutical industry professionals around the world believe that employee safety and supply chain disruption are their businesses’ number one concerns from COVID-19, the latest survey data from GlobalData, a leading data and analytics company, suggests. GlobalData’s latest report, ‘Coronavirus Disease 2019 (COVID-19) Sector Impact: Pharmaceutical Trade and Supply Chain Survey – Q1 2020’, reveals that 21% […]
Read more

Favipiravir exports during COVID-19 outbreak reaffirm India’s position as ‘pharmacy to the world’, says GlobalData

Following the news that India-based Strides Pharma has developed and commenced the export of generic favipiravir antiviral tablets to potentially treat COVID-19 infection; Sasmitha Sahu, Pharma Analyst at GlobalData, a leading data and analytics company, offers her view: “This is an opportunity to reaffirm that India is indeed the ‘pharmacy to the world’. As the […]
Read more

Treatments for ARDS important for battling COVID-19

As the COVID-19 pandemic continues, pharmaceutical companies are working on finding treatments to lessen the symptoms of the disease. Several drugs are being investigated for their ability to reduce acute respiratory distress syndrome (ARDS), a cause of death in COVID-19 patients. Finding a treatment for this syndrome will play an important role in decreasing the […]
Read more

Wockhardt’s QIDP status for WCK 6777 reflects unmet need and untapped market opportunity, says GlobalData

India-based Wockhardt Ltd has recently received US FDA qualified infectious disease product (QIDP) status for WCK 677 (currently filed Investigational New Drug Application/Clinical Trial Application (IND/CTA)) to treat complicated urinary tract infections, including pyelonephrits and intra-abdominal infections. WCK 6777 targets multidrug resistance bacterial infections where unmet need is high, translating to an untapped market opportunity, […]
Read more

Incyte and Eli Lilly may have JAK inhibitor mechanistic edge over Pfizer for COVID-19 while Theravance may be limited by nebulised approach

Interest in a class of drugs called JAK inhibitors to manage COVID-19 is building, and with three such therapies already approved for other diseases, the race to repurpose these treatments has kicked off. Incyte’s Jakafi and Eli Lilly’s Olumiant may have mechanism edge over Pfizer’s Xeljanz, according to reporting by Reynald Castañeda, Pharma Writer for the Investigative News team at […]
Read more

SeaStar Medical to test immunomodulating device for the treatment of COVID-19 patients

Following the announcement that SeaStar Medical will initiate a pilot study of aselective cytopheretic device (SCD) in COVID-19 patients; Azadeh Laffafian, Medical Device Analyst at GlobalData, a leading data and analytics company, offers her view: “SeaStar’s SCD targets proinflammatory neutrophils and monocytes during continuous renal replacement therapy (CRRT) to combat cytokine storm in severely ill […]
Read more

Branded digital support for rheumatoid arthritis patients in Japan looks competitive and encouraging, says GlobalData

The rheumatoid arthritis (RA) treatment landscape in Japan is highly competitive with many novel disease-modifying anti-rheumatic drugs (DMARDs). To stay ahead of the competition, the branded support offered to RA patients by companies marketing these drugs looks competitive and encouraging, says GlobalData, a leading data and analytics company. According to GlobalData’s report, ‘Rheumatoid Arthritis: Global […]
Read more

Gilead’s remdesivir new standard of care against COVID-19, according to Fauci, but logistics of remdesivir distribution remains unclear

Following the news that Gilead’s antiviral remdesivir has met its primary endpoint in a clinical trial run by the National Institute of Allergy and Infectious Diseases (NIAID) in moderate to severe hospitalized COVID-19 patients and NIAID Director Dr. Fauci describing remdesivir as likely the new standard of care; Philipp Rosenbaum, PhD, Infectious Diseases Analyst at […]
Read more

Dapnat launch to boost Natco’s presence in India’s diabetes market but concerted efforts required, says GlobalData

India-based Natco Pharma has recently launched a generic version of AstraZeneca’s patented anti-diabetes drug Forxiga (dapagliflozin). Natco’s sodium glucose co-transporter-2 (SGLT2) inhibitor, Dapnat, is indicated for the treatment of type 2 diabetes (T2D), and is expected to boost the company’s overall presence within the Indian diabetes market, says GlobalData, a leading data and analytics company. […]
Read more

COVID-19 vaccine timeframe likely to be longer than 12 months

As the COVID-19 pandemic continues, developing a vaccine for the disease becomes a pressing manner, but a reasonable time frame for accomplishing a working vaccine may be longer than 12 months. Considering vaccines typically take years to develop, expectations surrounding the timeframe for a vaccine should be tempered. As COVID-19 therapeutics could be available in […]
Read more

Roche’s Actemra a possible candidate for severe COVID-19 treatment

Roche’s Actemra (tocilizumab) generated $687m in the first quarter of 2020, a 30% increase compared to the same period in 2019, due to evidence of effective treatment in severe COVID-19 patients experiencing respiratory failure. However, Actemra’s Q1 sales increase may be a one-off occurrence as Kevzara fell short in its Phase II trial, says GlobalData, […]
Read more
,

NHS collaborates with leading technology providers to develop COVID-19 response data platform

The National Health Service’s (NHS) data platform will help the country implement a co-ordinated and effective response to the rapidly evolving COVID-19 crisis in the UK, says GlobalData, a leading data and analytics company. Kathryn Whitney, MSc, GlobalData Director of Thematic Analysis, comments: “This data platform will give key decision makers in the NHS real-time […]
Read more

Two-thirds of COVID-19 cases may be undiagnosed

Up to 80% of COVID-19 cases are mild or asymptomatic and therefore unlikely to be diagnosed. Determining what percentage of the population is asymptomatic will allow us to know how close we are to achieving herd immunity for COVID-19 and when it is safe to loosen isolation and quarantine restrictions, says GlobalData, a leading data […]
Read more

Clinical trials evaluating pain and mental health conditions are the neurology indications affected most by COVID-19, says GlobalData

Clinical trials evaluating pain and mental health conditions are the neurology indications most affected by the ongoing COVID-19 pandemic, says GlobalData, a leading data and analytics company. A combination of lockdown measures as well as the need to re-prioritize existing healthcare resources in a hospital setting are all essential steps being taken to combat the […]
Read more
1 … 94 95 96 97 98 … 108